| Title: |
Evolving impact of long-term survival results on metastatic melanoma treatment |
| Authors: |
Michielin, Olivier; Atkins, Michael B; Koon, Henry B; Dummer, Reinhard; Ascierto, Paolo Antonio |
| Source: |
Michielin, Olivier; Atkins, Michael B; Koon, Henry B; Dummer, Reinhard; Ascierto, Paolo Antonio (2020). Evolving impact of long-term survival results on metastatic melanoma treatment. Journal for ImmunoTherapy of Cancer, 8(2):e000948. |
| Publisher Information: |
BioMed Central |
| Publication Year: |
2020 |
| Collection: |
University of Zurich (UZH): ZORA (Zurich Open Repository and Archive |
| Subject Terms: |
Dermatology Clinic; 610 Medicine & health; Immunology; Immunology and Allergy; Molecular Medicine; Cancer Research; Oncology; Pharmacology |
| Description: |
Melanoma treatment has been revolutionized over the past decade. Long-term results with immuno-oncology (I-O) agents and targeted therapies are providing evidence of durable survival for a substantial number of patients. These results have prompted consideration of how best to define long-term benefit and cure. Now more than ever, oncologists should be aware of the long-term outcomes demonstrated with these newer agents and their relevance to treatment decision-making. As the first tumor type for which I-O agents were approved, melanoma has served as a model for other diseases. Accordingly, discussions regarding the value and impact of long-term survival data in patients with melanoma may be relevant in the future to other tumor types. Current findings indicate that, depending on the treatment, over 50% of patients with melanoma may gain durable survival benefit. The best survival outcomes are generally observed in patients with favorable prognostic factors, particularly normal baseline lactate dehydrogenase and/or a low volume of disease. Survival curves from melanoma clinical studies show a plateau at 3 to 4 years, suggesting that patients who are alive at the 3-year landmark (especially in cases in which treatment had been stopped) will likely experience prolonged cancer remission. Quality-of-life and mixture-cure modeling data, as well as metrics such as treatment-free survival, are helping to define the value of this long-term survival. In this review, we describe the current treatment landscape for melanoma and discuss the long-term survival data with immunotherapies and targeted therapies, discussing how to best evaluate the value of long-term survival. We propose that some patients might be considered functionally cured if they have responded to treatment and remained treatment-free for at least 2 years without disease progression. Finally, we consider that, while there have been major advances in the treatment of melanoma in the past decade, there remains a need to improve outcomes for the patients with ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
2051-1426 |
| Relation: |
https://www.zora.uzh.ch/id/eprint/192813/1/857_Michielin_O._et_al._Evolving_impact_of_long-termn_survival_results_on_metastatic_melanoma_treatment_Journal_for_Immunotherapy_of_Cancer_2020.pdf; info:pmid/33037115; urn:issn:2051-1426 |
| Availability: |
https://www.zora.uzh.ch/id/eprint/192813/ |
| Rights: |
info:eu-repo/semantics/openAccess ; Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) ; http://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.D3C12FAD |
| Database: |
BASE |